Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Atacand 8 mg tablets
Medicines register · Ireland

Atacand 8 mg tablets

Authorisation PPA1463/031/001 · IMED Healthcare Ltd.,

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 18 Nov 2026
Licence holder
IMED Healthcare Ltd., (all products →)
Active substance
Candesartan cilexetil
Dosage form
Tablet
Route of administration
Oral use
ATC codes
C09CA, C09CA06
First authorised
05/02/2010
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Parallel importation notified in accordance with Article 76(3) of Directive 2001/83/EC

Candesartan cilexetil: supply and approvals

38 authorised products on the HPRA list contain Candesartan cilexetil. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 17 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 17 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 17 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Parallel import (PPA). A parallel product authorisation: the HPRA allows this product to be imported from another EU or EEA country and sold in Ireland. It has been authorised for 16 years (since 5 February 2010). The HPRA list does not say whether it is on sale.

Other medicines with Candesartan cilexetil in Ireland

37 other products on the HPRA list contain Candesartan cilexetil, from 7 licence holders; 15 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Atacand 16 mg tabletsCHEPLAPHARM Arzneimittel GmbHNational authorisation (PA)Marketed
Atacand 8 mg tabletsCHEPLAPHARM Arzneimittel GmbHNational authorisation (PA)Marketed
Atacand Plus 16 mg/12.5 mg tabletsCHEPLAPHARM Arzneimittel GmbHNational authorisation (PA)Marketed
Candesartan 16 mg tabletsAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Candesartan 4 mg TabletsAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Candesartan 8 mg tabletsAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Candesartan Clonmel 16 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Candesartan Clonmel 4 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Candesartan Clonmel 8 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Candesartan Hydrochlorothiazide Krka 16mg/12.5mg tabletsKRKA, d.d., Novo mestoNational authorisation (PA)Marketed
Candesartan Krka 16 mg tabletsKRKA, d.d., Novo mestoNational authorisation (PA)Marketed
Candesartan Krka 4 mg tabletsKRKA, d.d., Novo mestoNational authorisation (PA)Marketed

All 38 products with Candesartan cilexetil →

Other substances in ATC group C09CA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 9 other active substances share the group C09CA with this product:

Telmisartan (34) · Valsartan (26) · Irbesartan (24) · Losartan potassium (18) · Olmesartan medoxomil (18) · Hydrochlorothiazide (4) · Azilsartan medoxomil (3) · Eprosartan (3) · Hydrocholothiazide (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

IMED Healthcare Ltd., holds 178 products on the HPRA list, with 119 different active substances; 1 of the products is marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 18 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.